• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

The Institute of Cancer Research - Articles and news items

head and neck cancer

‘Game-changing’ immunotherapy doubles head and neck cancer survival

Industry news, Z Homepage promo / 10 October 2016 / Niamh Louise Marriott, Digital Content Producer

An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer…

Gene activity linked to breast cancer survival

Industry news / 18 August 2016 / The Institute of Cancer Research, London

In a study of nearly 2000 patients, researchers found that women whose tumours had high F12 activity and low STC2 activity had a 32% chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10% chance of dying…

Stomach cancer with copies of FGFR2 gene more susceptible to AZD4547

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

Scientists are able to identify patients with stomach cancer who are most likely to respond to AZD4547 by measuring copies of the FGFR2 gene in the bloodstream…

Children with cancer to be offered gene testing in personalised treatment initiative

Industry news / 31 March 2016 / Victoria White

Children with cancer will be offered testing for genetic mutations in their tumours as part of an initiative to personalise children’s cancer treatment…

NICE recommends abiraterone for some prostate cancer patients

Industry news / 21 March 2016 / Victoria White

Professor Paul Workman of The Institute of Cancer Research, which discovered abiraterone, said the recommendation was “a big victory for men”…

Lapatinib and trastuzumab shrinks HER2+ breast cancers within 11 days

Industry news / 11 March 2016 / Victoria White

A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours. The trial set out to study the biological effects of the drug combination by measuring biological markers of cellular proliferation after 11 days of therapy…


Palbociclib plus fulvestrant slows breast cancer spread

Industry news / 3 March 2016 / Victoria White

In a study, some 67% of 347 women given palbociclib plus fulvestrant showed clinical benefit compared with 40% of 174 women given placebo plus fulvestrant…

Ecosystem Diversity Index

ICR scientists develop Ecosystem Diversity Index for breast cancers

Industry news / 16 February 2016 / Victoria White

Scientists have developed a test called the Ecosystem Diversity Index which combines methods used by ecologists with a powerful cancer imaging technique…

NICE says ‘yes’ to Opdivo (nivolumab) in melanoma

Industry news / 22 January 2016 / Victoria White

NICE recommends that nivolumab is made available on the NHS as a treatment option for patients with advanced (unresectable or metastatic) melanoma…

EC approves Imlygic as Europe’s first oncolytic immunotherapy

Industry news / 18 December 2015 / Victoria White

The European Commission has approved the use of Amgen’s Imlygic (talimogen laherparepvec) for the treatment of adults with unresectable melanoma…

Oxygen-enhanced MRI detects hypoxia within tumours

Industry news / 10 December 2015 / Victoria White

Teams at The University of Manchester and The Institute of Cancer Research, London, have described detailed development of oxygen-enhanced magnetic resonance imaging (MRI) technology to map areas of oxygen deprivation within tumours…

Landmark clinical trial shows olaparib can treat prostate cancer

Industry news / 29 October 2015 / Victoria White

The trial is a milestone in cancer treatment as the first to show the benefits of ‘precision medicine’ in prostate cancer…